National
16 Democratic senators uncommitted on ENDA
Despite uncertainties, House to forge ahead on job bias bill
U.S. Rep. Barney Frank said ENDA supporters should ‘call senators and lobby them’ to help build momentum for the bill in the Senate. (Photo by Joe Tresh)
With supporters of the Employment Non-Discrimination Act expecting a favorable House vote on the measure in May or June, LGBT lobbyists are turning their attention to 16 Democratic senators who have yet to sign on as co-sponsors of the legislation.
The bill, also known as ENDA, bars employment discrimination based on someone’s actual or perceived sexual orientation and gender identity.
Its supporters say it’s needed to end job discrimination in 29 states, where it remains legal to fire or refuse to hire someone who’s gay, lesbian or bisexual. Supporters also note that employers in 38 states can fire or refuse to hire someone solely because of their gender identity or expression, a practice the bill would similarly prohibit.
Multiple sources have told DC Agenda that supporters in the Senate don’t appear to have the 60 votes needed to overcome a filibuster that Republican opponents are expected to invoke to block an up or down floor vote.
“I’ve tried to get a sense of what’s going on here,” said Rep. Barney Frank (D-Mass.), ENDA’s lead sponsor in the House. “But I think the best thing I can do about the Senate and ENDA is to get it passed [in the House] and send it over there.”
Frank’s advice for ENDA backers worried about the Senate is to “call senators and lobby them” rather than dwell too much on “arm chair strategizing.”
But with the 2010 congressional elections fast approaching, only two GOP senators have so far committed to vote for ENDA, making it essential for supporters to line up most of the 16 uncommitted Democrats to secure the bill’s passage in the Senate.
Nearly all political observers predict the Democrats’ majorities in the House and Senate will shrink as a result of the November election, making it far more difficult to pass ENDA and other LGBT rights bills next year.
As of this week, there were 45 Senate co-sponsors of ENDA, along with chief sponsor Sen. Jeff Merkley (D-Ore.), bringing the total committed votes to 46. Of the 46, 42 are Democrats and two are independents. Maine senators Olympia Snowe and Susan Collins are the only Senate Republicans that have signed on as co-sponsors.
Thirty-nine Republican senators have declined to co-sponsor the bill compared to the 16 Democrats who chose not to become a co-sponsor. Sen. Jim Webb (D-Va.) signed on as a co-sponsor on March 10, reducing the number of uncommitted Democrats from 17 to 16.
For the first of a series of reports on the Democratic senators uncommitted on ENDA, DC Agenda contacted experts and activists in the states that five of those senators represent, seeking to assess how they would vote if the measure reaches the Senate floor sometime this year.
The five senators include Blanche Lincoln (D-Ark.), Mark Pryor (D-Ark.), Thomas Carper (D-Del.), Evan Bayh (D-Ind.), and Clare McCaskill (D-Mo.). Spokespeople for the five did not return calls this week seeking to determine their position on ENDA.
Many political observers in Arkansas believe Lincoln is facing an uphill fight in her re-election bid, with the state’s lieutenant governor, Bill Halter, challenging her in the Democratic primary. As of April 1, each of four Republicans seeking the nomination to oppose her in the general election was ahead of her in a Rasmussen public opinion poll by margins of 51 percent to 36 percent.
Officials with the state’s sole statewide LGBT group, Center for Artistic Revolution, did not respond to calls for comment by press time.
Hastings Wyman, editor of Southern Political Report, a recognized authority on politics and elections in the South, said support for ENDA would not help Lincoln in the current political environment.
“I can’t say how she would vote on ENDA, but the politics would say it would help her if she did not vote for it,” he said.
Wyman noted that Pryor, who is not up for re-election this year, has a record as a moderate on most issues, even though he projects an image of a conservative Democrat.
“I would not be surprised if he voted for it,” he said.
Steve Elkins, executive director of Camp Rehoboth, an LGBT advocacy group and community center in Rehoboth Beach, Del., said he has spoken with Carper at gay-related events and believes the state’s senior senator would vote for ENDA.
“He has been to Camp Rehoboth and has attended a number of LGBT events,” including meetings of the state’s LGBT Democratic group, Stonewall Democrats of Delaware, Elkins said. “There is no reason for me to think he would not vote for the bill.”
Delaware’s other senator, Democrat Ted Kaufman, who was appointed to fill the Senate seat vacated when former Sen. Joe Biden was elected vice president, is an ENDA co-sponsor.
By comparison, Indiana political consultant Mark St. John, a member of the board of the statewide LGBT group Indiana Equality, said Bayh has a longstanding reputation as a cautious politician and has yet to give any indication of how he would vote on ENDA.
“I wish I had a better answer,” he said. “Evan is certainly Mr. Cautious on that issue … but this is not to say he would vote no on ENDA. He has always held his cards close to his chest.”
St. John said Indiana Equality is lobbying Bayh to support both ENDA and a proposal to repeal “Don’t Ask, Don’t Tell,” the law that bars gays, lesbians and bisexuals from serving openly in the military.
Although McCaskill’s office has not responded to at least two inquiries from DC Agenda seeking her position on ENDA, A.J. Bockelman, executive director of the Missouri statewide LGBT group Promo, said McCaskill told members of the group at a meeting in Kansas City in February that she supports ENDA and would vote for it.
“We have talked to her office about the trans provisions in the bill and she is OK with that,” Bockelman said.
Sources familiar with ENDA have said several senators and House members raised objections to the transgender provision, a development that prompted Frank to work with transgender activists to come up with proposed revisions in the bill’s language pertaining to gender identity. The changes are expected to be disclosed when the House version of the bill is marked up in committee in late April or early May.
“Everyone signed off on the changes,” said one transgender activist, who spoke on condition of anonymity. “We’re not crazy about them, but they’re acceptable and they’ll help us get the bill passed.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Long-awaited ‘Pillion’ surpasses the sexy buzz
